EB Report

By Margaret Liu-Presdent Elect
Fellow ISV Members: 2015 is an election year, so please consider whether you are interested in serving the Society or know of someone who would contribute. The positions include 3 Officers: President-elect, Secretary and Treasurer, as well as 6 Executive Board members. If you would like to nominate someone for a position, please note that in addition to an obvious requirement that the candidate is a member of ISV, the candidate must be willing to commit the necessary time to fulfill the duties of the position. Duties for the Executive Board members include monthly teleconferences as well as participation in committee assignments. The President-elect serves in that position for two years before becoming President. The Secretary takes minutes of the Executive Board meetings/teleconferences, maintaining members rolls and contact information in addition to other secretarial duties. The Treasurer is responsible for all financial matters related to membership dues, the annual Congress, filing of US tax forms (ISV is a tax-exempt, non-profit US 501(c) (3) institution). Nominations should include a short statement from the candidate describing his/her interest in and commitment to the position, a brief bio, and the nomination letter(s), i.e., one nomination from a Board member, or a nomination for two general members. Self-nominations are permitted as long as the necessary number of nomination letters is included. 
Voting can be accomplished by email or in person at the annual ISV meeting held during the Congress (Tuesday, 20 October 2015) after receipt of the candidate list, which will be two weeks prior to the annual meeting. Please send nomination documentation to both: Secretary Annie De Groot at annieD@epivax.com and President-elect Margaret Liu at Liu@ProTherimmune.com

9th Vaccine & ISV Congress

By Margaret Liu, Co-Chair of VC9.

The 9th Annual Vaccine and ISV Congress 18-20 October 2015 in Seoul, South Korea is fewer than 45 days away. The program is currently listed on the Congress website, and nearly 300 oral and poster presentations are planned. Remember: Join ISV (free this year!) before registering for the Vaccine Congress and you will save $100 dollars on registration.

The aim of the 9th Vaccine & ISV Congress is to provide a forum for researchers, professionals and policy makers to present, share and exchange the latest cutting edge discoveries in vaccines and vaccinations. We hope to facilitate new collaborations between experts in the field and inspire new and innovative ideas in vaccine development.

In addition, a Career Development Workshop: Identifying & Achieving your Dream Job will be held Tuesday, 20 October 2015. This workshop is intended to provide young investigators (students, post-docs, and early faculty), the opportunity to get advice from senior internationally known scientists, both MDs and PhDs. The panelists will give brief introductions about their training and careers, highlighting key factors such as mentor selection, international training, tips for obtaining funding, ways to increase visibility, career options, etc. Attendees will have the opportunity to ask their own questions as well.

The panel will also be held for trainees unable to attend the Congress, on Saturday, 17 October 2015 at the International Vaccine Institute on the Seoul National University Campus at 17:00. Please see the Congress website for more information.

Point of View

International Society of Vaccines - A Brief Introduction for New Members
By Dr. Shan Lu

While the concept of vaccination has a much longer history than many disciplines of the biological sciences, a worldwide professional organization for vaccinologists did not come into existence until the last two decades. For many years, vaccines were only considered a specific type of clinical product and most of those working on vaccines were from pharmaceutical companies tasked with developing and manufacturing vaccines. There are, in fact, professional groups that have an overlapping interest in vaccines, Continued on page 2...
such as the International Alliance of Biological Standards (IABS), whose members are experienced in either the manufacturing of biologicals (mainly vaccines) or the regulatory review of vaccines at government agencies, such as the US FDA. In addition, individual country-based organizations were formed in the past for vaccine professionals in certain countries, such as the Japanese Society for Vaccines (JSV).

Vaccines received much more attention by academic researchers in the 1990s, represented by the emergence of conferences such as “Modern Approaches to New Vaccines” organized by the Cold Spring Harbor Laboratory. With the rapid progress of immunology and a more in-depth understanding of existing and emerging pathogens, more and more basic biological scientists became interested in vaccine-related research. Discoveries, such as DNA vaccine technology in the early 1990s, challenged the previous idea that vaccines had reached their maximum potential, leading to the notion that they had limited future growth except in the area of product development. There has been a growing consensus that more fundamental research is needed, particularly to address issues around development of effective vaccines against more challenging infectious diseases such as tuberculosis, malaria, and AIDS.

The need for a worldwide professional organization for scientists working on vaccine research became apparent. The International Society of Vaccines (ISV) was formally established on March 21, 1994. In the following 14 years, ISV has tried various models to organize vaccinologists working in different parts of the world, either by hiring professional service groups or working with various commercial or non-for-profit organizations to run ISV activities. Unfortunately, none of these models were effective because there was no dedicated organizational structure run by ISV itself and there was no continued effort to recruit and grow ISV membership.

In 2008, ISV went through a major reorganization. A new organizational structure was established with a new generation of leadership, and the following have been accomplished since: 1) ISV is currently registered with the State of Massachusetts, USA as a legal corporate entity; 2) ISV received an independent tax filing status from the US Internal Revenue Service (IRS); 3) subsequently, ISV received non-for-profit status with both the State of Massachusetts and the US IRS as a tax exempt organization; 4) ISV went through three open elections (in 2009, 2011, 2013) by a fully transparent and democratic process to elect members of Executive Board (EB), including ISV Officers; and 5) ISV Fellow, a special membership status, was established to recognize those people who have made a significant contribution to the field of vaccines. To read more, visit our website.

---

**Paper of the Month**

**Modeling the long-term antibody response of a hepatitis E vaccine**

Shu Chen, Zhi Zhou, Fei-Xue Wei, Shou-Jie Huang, Zhong Tan, Ya Fang, Feng-Cai Zhu, Ting Wu, Jun Zhang, Ning-Shao Xia

1State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen 361102, China
2Key Laboratory of Health Technology Assessment of Fujian Province University, School of Public Health, Xiamen University, Xiamen 361102, China
3School of Mathematical Sciences, Xiamen University, Xiamen 361005, China
4Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, Jiangsu Province, China

**Background:** The first commercialized hepatitis E vaccine, HEV 239, has been shown to be safe and highly immunogenic, the protection as well as the vaccine-induced anti-HEV maintained for at least 4.5 years. However, the longer term persistence of the vaccine-induced anti-HEV responses is unknown.

Click here for the link.

**Poll of the Month**

Which of the following non-infectious disease, non-cancer vaccine targets is most interesting to you?

1. Contraception
2. Alzheimer’s
3. Other Neurodegenerative Disease
4. Allergen Vaccines
5. Substance Abuse

Provided by Danielle Basore

Visit our website to record your vote!

**ISV FELLOW OF THE MONTH**

Dr. Annie De Groot is a physician and Research Professor of Biotechnology at the University of Rhode Island and co-founder and CEO/CSO of the immunoinformatics company EpiVax. She founded and directs the Institute for Immunology and Informatics at the University of Rhode Island, one of the first centers of excellence for immunoinformatics-driven vaccine design in the world. Dr. De Groot graduated from Smith College with a BA and from the Pritzker School of Medicine at University of Chicago. She completed her residency in internal medicine at Tufts New England Medical Center in 1986 and completed fellowships in Parasitology and Vaccine Research at the NIH (1989) and in Infectious Disease at the Tufts New England Medical Center (1993).

To read more, visit our website.

---

ISV is a 503c Non-Profit organization. If you have questions or comments please contact us by visiting our website.
Rabies is among the most terrifying viruses to get. According to the Centers for Disease Control, “once clinical signs of rabies appear, the disease is nearly always fatal.” (Really: there have been fewer than 10 documented cases of survival once symptoms appear.) Luckily for us—and our pets—Louis Pasteur developed a vaccine that can stop things from getting to that point.

The first time the vaccine was ever administered to a human—on this day in 1885—was by Pasteur himself. Knowing that the disease was otherwise fatal, both doctor and patient (or, rather, patient’s mother) were willing to risk whatever harm might come from the injection, which had only been tested on dogs. As TIME recounted in 1939: One hot July morning in 1885, feverish little Joseph Meister (pictured) was dragged by his frantic mother through the streets of Paris in search of an unknown scientist who, according to rumors, could prevent rabies. Click to read more.

Newsletter articles chosen by Dr. Ted Ross (University of Georgia)
Newsletter design and edit by Chalise Bloom (University of Georgia)